MLD & Gene Therapy
Metachromatic leukodystrophy (MLD) is a rare autosomal recessive lysosomal storage disorder caused by deficiency of arylsulfatase A (ARSA), leading to sulfatide accumulation and progressive demyelination. Current therapeutic approaches include enzyme replacement, bone marrow transplantation, and gene therapy. Among these, ex vivo lentiviral vector (LV)-mediated gene transfer into hematopoietic stem cells (HSCs) has shown exceptional promise by enabling long-term ARSA expression and cross-correction in the central nervous system.
At Creative Biolabs, we specialize in developing next-generation LVs for MLD, featuring advanced self-inactivating (SIN) designs and moderately active internal promoters to maximize efficacy while minimizing integration-dependent genotoxicity. Our platforms support preclinical development from vector design to high-titer production.
SIN Design
Self-inactivating LTRs reduce risk of insertional oncogenesis while preserving high-titer production.
Optimized Promoter
Moderate-strength internal promoters drive physiological ARSA levels without overexpression‑related toxicity.
HSPC Transduction
High-efficiency gene transfer into CD34+ cells with validated protocols for controlled vector copy number (VCN) in the research range.
MLD Vector Services
ARSA Expressing Vectors
Lentiviral vectors encoding human ARSA cDNA under optimized promoters for robust and sustained enzyme production.
Codon-optimized human ARSA driven by moderate-strength constitutive promoters (e.g., EF1α, PGK) or lineage-specific promoters (e.g., CD11b) to match physiological expression.
Options include ARSA with C-terminal tags (FLAG/HA) for detection, or fusion with GFP for tracking. Also available: saposin B (SAP-B) expressing vectors for rare activator-deficient MLD.
Validated in ARSA‑null cell lines and primary HSPCs with >80% transduction efficiency and sustained sulfatide reduction.
Self-Inactivating (SIN) Vectors
Advanced SIN LTR design to eliminate enhancer/promoter activity of the viral LTR after integration, reducing genotoxicity risk.
Deletion in U3 region of 3' LTR results in transcriptional inactivation of both LTRs upon integration. Internal promoter drives ARSA without interference from viral enhancers.
In long-term follow-up studies using murine models, no clonal outgrowth or hematologic malignancy was observed, confirming reduced insertional mutagenesis potential.
HSC Transduction Optimization
Customized protocols to maximize gene transfer into human CD34+ hematopoietic stem and progenitor cells while preserving stemness.
Use of poloxamer, prostaglandin E2, or cyclosporine H to boost LV uptake without cytotoxicity. Protocols tailored for fresh or cryopreserved cells.
Titration to achieve target VCN (0.5–2 copies/cell) for therapeutic efficacy without genotoxicity. Quality control includes VCN analysis by ddPCR.
Safety & Genotoxicity Assessment
Integrated services to evaluate vector safety, including integration site analysis and in vivo tumorigenicity studies.
LAM-PCR or NGS-based mapping of vector integration sites to assess clonal skewing and proximity to oncogenes.
Long-term monitoring in immunodeficient mice transplanted with transduced human HSPCs to evaluate hematologic abnormalities.
Technical Capabilities
Optimizing the vector payload for maximum efficacy and minimal risk.
Self-Inactivating Design
Our SIN vectors feature a 400‑bp deletion in the U3 region of the 3' LTR, which is copied to the 5' LTR during reverse transcription, resulting in transcriptional inactivation of both LTRs. This prevents activation of nearby genes and reduces the risk of insertional mutagenesis.
-
Enhanced SafetyIn preclinical studies, SIN vectors showed no evidence of clonal dominance or leukemia up to 9 months post-transplantation.
-
Moderate Internal PromoterWe use promoters like PGK or short EF1α to drive ARSA at levels comparable to endogenous expression, avoiding metabolic burden.
High‑Efficiency HSPC Transduction
Achieving therapeutic VCN in human CD34+ cells requires optimized culture conditions and vector formulations.
-
Proprietary Enhancer CocktailCombination of cytokines and small molecules (e.g., SR1, UM171) to maintain stemness while maximizing LV uptake.
-
Scalable ProductionSuspension culture in serum‑free medium yields titers >1×10⁹ TU/mL after concentration, sufficient for large animal studies.
Production & Quality
cGMP‑like manufacturing processes ensure high purity and consistency for preclinical studies.
| Parameter | Specification | Benefit for MLD |
|---|---|---|
| Titer (Physical) | > 1 x 10⁹ VP/mL | Allows low MOI transduction of HSPCs, minimizing cytotoxicity. |
| Purity | >95% (HPLC) | Removal of empty capsids and process‑related impurities reduces immunogenicity. |
| Envelope | VSV-G (standard), RDTR, or measles | Choice of pseudotype for HSPC or neuronal targeting. |
Designable Lentiviral Vector Types
We offer a range of vector architectures tailored to MLD gene therapy research, from basic ARSA expression to advanced safety switches.
| Vector Type | Design Features | Application Context |
|---|---|---|
|
ARSA Expression(constitutive)
|
Human ARSA cDNA under PGK, EF1α, or CAG promoter. Optional IRES‑GFP or 2A‑reporter for tracking. | Basic screening of ARSA activity in cell lines or primary cells; enzyme reconstitution studies. |
|
SIN Vectors(self-inactivating)
|
SIN LTR design with deletion in U3. Internal promoter drives ARSA; no enhancer activity from LTR. | Preclinical safety studies; vectors intended for clinical translation where genotoxicity risk must be minimized. |
|
Inducible Vectors
|
Promoter with rtTA; doxycycline‑controlled ARSA expression. Minimal leakiness. | Dose‑response studies, investigating therapeutic windows, or controlling expression in differentiation protocols. |
|
Excisable Vectors(Cre‑LoxP)
|
ARSA cassette flanked by LoxP sites. Transient Cre expression removes vector after stable correction. | Generation of “footprint‑free” corrected cells for autologous transplantation with minimal residual viral DNA. |
|
Reporter Vectors(GFP/Luciferase)
|
ARSA‑2A‑GFP or bi‑cistronic constructs for easy tracking. Also available with firefly luciferase for in vivo imaging. | Biodistribution studies, sorting of transduced cells, and optimization of transduction protocols. |
Need a custom combination or a different promoter?
Application Scenarios
From disease modeling to preclinical efficacy studies, our vectors support every stage of MLD therapeutic development.
Patient‑Specific iPSCs
Generate iPSCs from MLD patient fibroblasts or PBMCs using our polycistronic reprogramming vectors. Differentiate into oligodendrocytes or neurons for in vitro disease modeling and drug screening.
Ex Vivo HSC gene therapy
Transduce autologous CD34+ cells from MLD patients with ARSA‑expressing SIN vectors. Transplant into murine models to evaluate multilineage reconstitution, enzyme activity, and sulfatide clearance in CNS.
Genotoxicity & Safety Studies
Perform integration site analysis (LAM‑PCR) and long-term follow-up in immunodeficient mice to monitor clonal behavior and confirm absence of insertional mutagenesis.
Direct CNS Delivery
Utilize AAV or LV pseudotyped with neurotropic envelopes for intrathecal or intracerebral injection in MLD mouse models. Monitor ARSA expression and behavioral outcomes.
Biomarker & Efficacy Assays
Quantify ARSA activity, sulfatide levels, and inflammatory markers in transduced cells or tissues. Use our validated protocols to assess therapeutic correction.
Tropism & Biodistribution
Test different LV pseudotypes (VSV‑G, RD114, BaEV) for optimal transduction of human HSPCs or neural cells. Perform qPCR for vector copies in tissues post-transplant.
Service Workflow
Streamlined vector construction, packaging, and quality control for MLD gene therapy projects.
Consultation & Strategy
We discuss your target cell type (HSPCs, fibroblasts, neurons), desired expression level, and safety requirements (SIN, excisable, etc.) to propose the optimal vector design.
Gene Synthesis & Cloning
ARSA cDNA (wild‑type or codon‑optimized) is synthesized and cloned into the lentiviral backbone (e.g., pCDH, pLVX) with your chosen promoter and reporter. Full sequencing confirmed.
Virus Packaging
Third‑generation packaging system in HEK293T cells. Large‑scale production in hyperflasks or bioreactors yields high‑titer crude harvest.
Purification & Titration
Concentration by ultracentrifugation or TFF, followed by ion‑exchange chromatography. Titers determined by p24 ELISA and qPCR (functional titer on HT1080 cells).
Delivery & Support
Vectors aliquoted and shipped on dry ice. We provide detailed transduction protocols, QC certificates, and optional functional validation (e.g., ARSA activity in transduced cell line).
What You Receive
All materials needed for your MLD gene therapy studies.
Transfer Plasmid
Sequence‑verified plasmid DNA (10 µg) containing your ARSA expression cassette, suitable for further modifications or re‑packaging.
High‑Titer Virus
Concentrated lentiviral particles (>1×10⁹ TU/mL) in PBS‑5% sucrose, aliquoted to avoid freeze‑thaw. Typical yield: 1–10 mL total.
QC Report
Certificate of Analysis including titer (p24 and qPCR), sterility, endotoxin (<1 EU/mL), mycoplasma, and replication‑competent lentivirus (RCL) testing.
Therapeutic Approaches for MLD
Lentiviral ex vivo gene therapy offers unique advantages in efficacy, safety, and durability compared to other modalities.
| Method | Efficacy | Durability | Safety | Best Use Case |
|---|---|---|---|---|
|
Lentiviral (ex vivo HSC)
|
High |
Lifelong (integrated) in HSCs |
SIN design minimizes risk no clonal dominance in long‑term studies |
Patients with late infantile or juvenile MLD; ongoing clinical trials (NCT01560182). |
| Enzyme Replacement Therapy | Moderate | Transient (weekly infusions) | No genotoxicity, but immunogenicity possible | Symptomatic treatment, does not cross BBB effectively. |
| Bone Marrow Transplant | High (if engrafted) | Lifelong | GVHD risk, donor availability | Early‑stage MLD if matched donor available; limited by transplant‑related mortality. |
| AAV (direct CNS) | Moderate | Years (episomal) | Low genotoxicity, but pre‑existing immunity | Focal delivery to brain; limited by vector spread and dilution in dividing cells. |
Frequently Asked Questions
Plan Your MLD Gene Therapy Project
To ensure the best results, please consider the following when requesting a quote:
- Target cells: Human CD34+ cells, fibroblasts, or cell lines?
- Vector type: Constitutive, SIN, inducible, or excisable?
- Promoter choice: PGK, EF1α, CD11b, or other?
- Reporter needed? GFP, luciferase, or none?
- Required titer and volume: Pilot (1 mL) vs. large-scale (10+ mL).
Get a Custom Vector Quote
Our vector design experts are ready to assist you in selecting the most efficient tools for your MLD research.
Start Your Project Today
Tell us about your project, and our experts will get back to you with a customized quote and proposal.
